Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QX002N in Active Ankylosing Spondylitis
CTR20212616Phase 2Completed
- Sponsor
- Qyuns Therapeutics
- Start
- Oct 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of crusekitug in ankylosing spondylitis (AS), sponsored by Qyuns Therapeutics. Started Oct 2021; status: completed.
02
Drugs
crusekitug
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on CTR20212616.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212616.